TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02417519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAR
Description: Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAR
Description: Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAR
Description: Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAR
Description: Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAR
Description: Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAR
Description: Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIR
Description: Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIR
Description: Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
Study: NCT02987881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise and nutritional counseling
Description: Moderate walking and running with nutritional counseling at study visits.
Study: NCT02171351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: effect of neuromuscular electrostimulation (NMES)
Description: Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuromuscular electrostimulation (NMES).
Study: NCT02417519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIR
Description: Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIR
Description: Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
Study: NCT02171351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: effect of neuro electrostimulation (NES)
Description: Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuro electrostimulation (NES)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: effect of voluntary contractions (VC)
Description: Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of voluntary contractions (VC)
Study: NCT01715298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
Study: NCT02417519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIR
Description: Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
Study: NCT01715298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Study: NCT00970554

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Patching of the sound eye for 30 minutes a day for 17 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telescopic magnification
Description: Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
Study: NCT03847493

Intervention type: OTHER
Intervention: Endothelial Glycocalyx
Description: Non-invasive assessment of endothelial glycocalyx dimensions.
Study: NCT02417519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIR
Description: Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
Study: NCT02580656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
Study: NCT02362022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
Study: NCT02425553

Intervention type: OTHER
Intervention: Diet
Description: High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)

Intervention type: OTHER
Intervention: Diet
Description: High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)

Intervention type: OTHER
Intervention: Diet
Description: Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)

Intervention type: OTHER
Intervention: Diet
Description: High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
Study: NCT02982759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Level Intervention
Description: The multi-level interventions will include activities at the individual level, family level, school level, and community level.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Genetic Newsletters
Description: The comparison will receive generic newsletters
Study: NCT00388999

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Study: NCT02209064

Intervention type: DEVICE
Group type: OTHER
Intervention: Pericardial access
Description: Access to the pericardium to enable further treatments.
Study: NCT04738383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Version 1: Paramedic
Description: Instead of a physician, who is constantly present, a paramedic is present next to the instructor during the sessions, who can give first aid in case of an emergency and bridge the time until the ambulance arrives on site. The physician still acts as a supervisor visiting the group roughly every six weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Version 2: Physician-on-call
Description: This version implicates that a physician is not physically present but is on call during the sessions and must be constantly accessible by phone and able to arrive within three minutes in case of an emergency. To ensure this, version two should be implemented in facilities, which are linked to cardiac or rehabilitation center.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Version 3: Trained instructor
Description: The sessions take place with the instructor only, who receives a comprehensive emergency training before and during the model phase and replaces the constantly present physician. Just like in the previous versions the physician still acts as a supervisor visiting the group roughly every six weeks.
Study: NCT03056053

Intervention type: DRUG
Group type: OTHER
Intervention: Zolpidem
Description: Commercially available tablets of zolpidem (5 or 10 mg) for oral use
Study: NCT02057770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation (TBI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Study: NCT02417519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
Study: NCT03619304

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: coffee beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: coffee beverage
Study: NCT00527059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan in addition to standard therapy
Description: intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone, beta-blockers,ecc
Study: NCT03619304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coffee
Description: coffee beverage
Study: NCT01503047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tonalin®
Description: Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
Study: NCT03229603

Intervention type: OTHER
Group type: OTHER
Intervention: Cluster of 3000 women
Description: An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
Study: NCT02684929

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: branched chain amino acids
Description: 15 (women) or 20 (men) grams of BCAA daily for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: branched chain amino acids
Description: 15 (women) or 20 (men) grams of BCAA daily for 3 months
Study: NCT04058496

Intervention type: OTHER
Intervention: Blood sampling
Description: Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission

Intervention type: OTHER
Intervention: Blood sampling
Description: Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission

Intervention type: OTHER
Intervention: Blood sampling
Description: Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
Study: NCT04943393

Intervention type: OTHER
Intervention: nointervention
Description: Nointervention

Intervention type: OTHER
Intervention: nointervention
Description: Nointervention
Study: NCT00835926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03950882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PXL770
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT01995383

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LS followed by NS diet condition
Description: LS diet period followed by NS diet period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LS followed by NS diet condition
Description: LS diet period followed by NS diet period
Study: NCT03619304

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: coffee beverage
Study: NCT03593551

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: five relaxation treatments and one control
Description: Five treatments are relaxation meditation tape, music tape, relaxation lighting, meditation tape plus lighting, and music plus lighting. The control session have no intervention, participants will just be asked to sit comfortably for 10 minutes.
Study: NCT00601159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
Study: NCT00707759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone
Description: Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone
Description: Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d
Study: NCT01579331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCT (PASCAL© Tonometer) IOP and OPA measurement
Description: Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve.
Study: NCT02831543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motireb 5/100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride citrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01036438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mepilex without Ag
Description: Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
Study: NCT03039101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal lavage
Description: determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal lavage
Description: determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Description: A small amount of allergen extract will be applied to one naris.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal allergen challenge
Description: A small amount of allergen extract will be applied to one naris.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epicutaneous skin testing
Description: Skin testing (prick) to determine allergies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: Peripheral blood draw

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral blood
Description: Peripheral blood draw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10Mg Tablet
Description: one pill orally, daily, for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: one pill orally, daily, for 1 week
Study: NCT02160236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol
Description: before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenoxicam
Description: before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: serum physiologic
Description: before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
Study: NCT01200589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: sourced locally from commercial stock

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
Study: NCT04085185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110+ Sintilimab
Description: IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110+ Sintilimab
Description: IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit.